Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai Hospital, tells us about the outcomes of the TITAN study in metastatic castration-resistant prostate cancer (mCRPC)

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai ...

Sandip Patel, MD, on treatment in the 2nd line setting following PD-L1 targeting agents

Dr. Patel, Assistant Professor of Medicine, Deputy Director, San Diego Center for Precision Immunotherapy, Co-Leader, Experimental Therapeutics (Phase 1), UC San Diego Moores Cancer Center, explains how to treat 2nd line patients who have received Keytruda or other PD-L1 targeting agents as a part of 1st line therapy

Dr. Patel, Assistant Professor of Medicine, Deputy Director, San Diego Center for Precision Immunotherapy, Co-Leader, Experimental Therapeutics (Phase 1), UC ...

Sandip Patel, MD, speculates on the impact of the RELAY trial presented at ASCO 2019

Dr. Patel, Assistant Professor of Medicine, Deputy Director, San Diego Center for Precision Immunotherapy, Co-Leader, Experimental Therapeutics (Phase 1), UC San Diego Moores Cancer Center, considers whether outcomes from the RELAY trial will impact the treatment of 1st line, EGFR mutant, non-small cell lung cancer (NSCLC)

Dr. Patel, Assistant Professor of Medicine, Deputy Director, San Diego Center for Precision Immunotherapy, Co-Leader, Experimental Therapeutics (Phase 1), UC ...

Che-Kai Tsao, MD, offers opinion on the results of the ENZAMET study in mHSPC

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai Hospital, offers interpretation of the ENZAMET study comparing testosterone suppression versus testosterone suppression and enzalutamide in metastatic hormone sensitive prostate cancer (mHSPC)

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai ...

Che-Kai Tsao, MD, discusses the current application of biomarkers in renal cell carcinoma

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai Hospital, on whether reliable biomarkers are available to help identify subsets of renal cell carcinoma (RCC) patients who are more likely to respond to therapies

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai ...

Saad Usmani, MD, FACP, considers data in smoldering MM coming out of ASCO 2019

Dr. Usmani, Chief, Plasma Cell Disorders Program, Director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute/Atrium Health, Clinical Professor of Medicine, UNC Chapel Hill School of Medicine, shares his impressions of the data in smoldering multiple myeloma (MM) presented at the 2019 ASCO Annual Meeting

Dr. Usmani, Chief, Plasma Cell Disorders Program, Director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute/Atrium Health, Clinical Professor of ...

Parameswaran Hari, MD, speculates on whether KRD will replace stem cell transplant

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, speculates on whether KRD will replace stem cell transplant

Dr. Hari, Professor of Hematology, Medical College of Wisconsin, speculates on whether KRD will replace stem cell transplant

Tomasz M. Beer MD, FACP, outlines results from Keynote-365 presented at ASCO 2019

Dr. Beer, Deputy Director, Knight Cancer Institute, Chief Medical Officer, Center for Early Detection Advanced Research, Oregon Health & Science University, tells us about the results of Keynote-365, investigating the use of pembrolizumab in metastatic castrate-resistant prostate cancer (CRPC)

Dr. Beer, Deputy Director, Knight Cancer Institute, Chief Medical Officer, Center for Early Detection Advanced Research, Oregon Health & Science ...

Shirish Madhav Gadgeel, MBBS, on treating patients who have already received PD-L1 targeting agents

Dr. Gadgeel, Mary Lou Kennedy Research Professor, Thoracic Oncology, Professor, Department of Internal Medicine, Division of Hematology/Oncology, Co-Leader, Thoracic Oncology Research Program, Rogel Cancer Center, University of Michigan, considers how to treat 2nd line patients who have received Keytruda or another PD-L1 targeting agent as a part of 1st line therapy

Dr. Gadgeel, Mary Lou Kennedy Research Professor, Thoracic Oncology, Professor, Department of Internal Medicine, Division of Hematology/Oncology, Co-Leader, Thoracic Oncology ...

Che-Kai Tsao, MD, on deciding between I-O + TKIs combinations indicated for the treatment of RCC

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai Hospital, explains how to decide between the various combinations of immuno-oncology (I-O) and TKIs indicated for the treatment of 2nd line renal cell carcinoma (RCC)

Dr. Tsao, Associate Professor of Medicine, Icahn School of Medicine at Mt Sinai, Medical Director, Ruttenberg Treatment Center, Mt. Sinai ...